Abstract
Trimethoprim-sulfamethoxazole (TMP-SMZ) is recommended as the treatment of choice for Stenotrophomonas maltophilia infections. However, when the administration of TMP-SMZ is not possible, alternative treatment options for S. maltophilia infections has not been clearly established. We compare the efficacy of tigecycline treatment with TMP-SMZ in nosocomial S. maltophilia infections during a 3-year period. For the treatment of S. maltophilia infection, 26 (57·8%) patients received TMP-SMZ and 19 (42·2%) patients received tigecycline. Culture positivity rate was 95·7% in TMP-SMZ group and 70·6% in tigecycline group at the seventh day (P = 0·028), whereas 26·3% versus 18·8% at the fourteenth day (P = 0·700). Clinical improvement was observed 69·2% in TMP-SMZ group and 68·4% in tigecycline group at the fourteenth day (P = 0·954). Mortality rates at the thirtieth day were respectively, 30·8 and 21·1% in TMP-SMZ and tigecycline groups (P = 0·517). There were no significant differences in mortality and clinical response rates between TMP-SMZ and tigecycline treatment. Tigecycline can be considered as an alternative option beyond TMP-SMZ in treatment of S. maltophilia infections.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Journal of Chemotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
